18:09 , Aug 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies suggesting inhibiting LOXL2 could help treat metastatic breast cancer. In a mouse model of breast cancer, mammary gland-specific knockout of LOXL2 decreased lung metastatic burden and the number circulating tumor...
17:31 , Jan 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Cardiovascular Patient sample and mouse studies suggest inhibiting NOS2 could help treat Marfan syndrome. In aortic tissue samples, levels of NOS2 were higher in patients and a mouse model of Marfan syndrome than in...
07:00 , Jun 23, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Thyroid hormone receptor

Hepatic disease INDICATION: Scleroderma; liver fibrosis Mouse studies suggest agonizing thyroid hormone receptor could help treat liver fibrosis and scleroderma-associated fibrosis. In a mouse model of liver fibrosis, the endogenous thyroid hormone receptor agonist triiodothyronine...
07:00 , Apr 16, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Wingless-type MMTV integration site family member 16 (WNT16)

Cancer INDICATION: Colon cancer In vitro studies suggest analogs of the natural product ellagic acid could help treat colon cancer. Chemical synthesis and in vitro testing of ellagic acid analogs identified a lead compound that...
07:00 , Aug 21, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Huntington's disease (HD) Microtubule-associated protein-t (MAPT; tau; FTDP-17) In vitro and mouse studies suggest depleting tau deposits could help treat HD. In a transgenic mouse...
07:00 , Apr 21, 2014 |  BioCentury  |  Emerging Company Profile

Minoryx: Mediating rare metabolism

Minoryx Therapeutics S.L. has two complementary strategies for developing therapies to treat inherited metabolic diseases involving enzyme deficiencies: identifying small molecule chaperones that can restore mutant enzyme function, and repurposing existing drugs to treat the...
07:00 , Aug 23, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Genetic mouse model of multiple myeloma (MM) A genetic mouse model of MM could help identify new compounds to treat the disease. Mice were engineered...
07:00 , Sep 16, 2010 |  BC Innovations  |  Distillery Techniques

Technology: Chemistry

Approach Summary Licensing status Publication and contact information Chemistry Improved variants of φ29 polymerase for DNA amplification φ29 polymerase variants could lead to faster and more efficient amplification of DNA. Fusion of a helix-hairpin-helix class...
07:00 , Jun 17, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology; nerve damage Glycogen dependent kinase 3 (GSK3); nuclear factor of activated T cells cytoplasmic calcineurin-dependent 3 (NFATC3; NFAT4); NFATC4 (NFAT3) A study in mice...
08:00 , Mar 5, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes Cyclin-dependent kinase 5 (CDK5); phosphoinositide 3-kinase (PIK3; PI3K); solute carrier family 2 (facilitated glucose transporter) member 4 (SLC2A4;...